PMID- 27200288
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160520
LR  - 20220410
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 6
DP  - 2016
TI  - Targeting mTOR in Pancreatic Ductal Adenocarcinoma.
PG  - 99
LID - 10.3389/fonc.2016.00099 [doi]
LID - 99
AB  - Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are 
      limited; however, new therapies targeting specific tumor-related molecular 
      characteristics may help certain patient cohorts. Emerging preclinical data have 
      shown that inhibition of mammalian target of rapamycin (mTOR) in specific 
      KRAS-dependent PDAC subtypes leads to inhibition of tumorigenesis in vitro and in 
      vivo. Early phase II studies of mono-mTOR inhibition have not shown promise. 
      However, studies have shown that combined inhibition of multiple steps along the 
      mTOR signaling pathway may lead to sustained responses by targeting mechanisms of 
      tumor resistance. Coordinated inhibition of mTOR along with specific 
      KRAS-dependent mutations in molecularly defined PDAC subpopulations may offer a 
      viable alternative for treatment in the future.
FAU - Iriana, Sentia
AU  - Iriana S
AD  - Department of Medicine, Cedars-Sinai Medical Center , Los Angeles, CA , USA.
FAU - Ahmed, Shahzad
AU  - Ahmed S
AD  - Department of Medicine, Cedars-Sinai Medical Center , Los Angeles, CA , USA.
FAU - Gong, Jun
AU  - Gong J
AD  - Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 
      Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, 
      USA.
FAU - Annamalai, Alagappan Anand
AU  - Annamalai AA
AD  - Department of Surgery, Cedars-Sinai Medical Center , Los Angeles, CA , USA.
FAU - Tuli, Richard
AU  - Tuli R
AD  - Department of Radiation Oncology, Cedars-Sinai Medical Center , Los Angeles, CA , 
      USA.
FAU - Hendifar, Andrew Eugene
AU  - Hendifar AE
AD  - Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center 
      , Los Angeles, CA , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160425
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC4843105
OTO - NOTNLM
OT  - KRAS
OT  - clinical trials
OT  - mTOR
OT  - pancreatic ductal adenocarcinoma
OT  - preclinical
EDAT- 2016/05/21 06:00
MHDA- 2016/05/21 06:01
PMCR- 2016/01/01
CRDT- 2016/05/21 06:00
PHST- 2016/02/26 00:00 [received]
PHST- 2016/04/11 00:00 [accepted]
PHST- 2016/05/21 06:00 [entrez]
PHST- 2016/05/21 06:00 [pubmed]
PHST- 2016/05/21 06:01 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2016.00099 [doi]
PST - epublish
SO  - Front Oncol. 2016 Apr 25;6:99. doi: 10.3389/fonc.2016.00099. eCollection 2016.